Prospects for Improved Antidepressants

Journal of Medicinal Chemistry

Volumn 38, Issue 23, 1995, Pages 4615-4633

  Broekkamp, C L E ^a   Leysen, D ^a   Peeters, B W M M ^a   Pinder, R M ^a  

^a NV ORGANON   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ADENOSINE A2 RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR; CLENBUTEROL; IMIPRAMINE; IPRONIAZID; LITHIUM; METITEPINE; MIANSERIN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; SEROTONIN AGONIST; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT;

DEPRESSION; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; REVIEW;

ANTIDEPRESSIVE AGENTS; DEPRESSION; DRUG THERAPY, COMBINATION; HUMAN; HYPOTHALAMUS; MOLECULAR STRUCTURE; PITUITARY GLAND; RECEPTORS, ADRENERGIC, ALPHA; RECEPTORS, GABA; RECEPTORS, SEROTONIN; SIGNAL TRANSDUCTION;

EID: 0028874344     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm00023a001     Document Type: Article

References (196)

1. Pinder, R. M.; Wieringa, J. H. Third-generation antidepressants. Med. Res. Rev. 1993, 13, 259-325.
2. Norman, T. R.; Leonard, B. E. Fast-acting antidepressants. Can the need be met? CNS Drugs 1994, 2, 120-131.
3. Pinder, R. M. The benefits and risks of antidepressant drugs. Hum. Psychopharmacol. 1988, 3, 73-86.
4. Farmer, R. D. T.; Pinder, R. M. Why do fatal overdose rates vary? Acta Psychiatr. Scand. 1989, 80 (Suppl. 354), 25-35.
5. Kapur, S.; Mieczkowski, T.; Mann, J. Antidepressant medications and the relative risk of suicide attempt and suicide. J. Am. Med. Assoc. 1992, 268, 3441-3445.
6. Henry, J. A.; Antao, C. A. Suicide and fatal antidepressant poisoning. Eur. J. Med. 1992, 1, 343-348.
7. Buckley, N. A.; Dawson, A. H.; Whyte, I. M.; Henry, D. A. Greater toxicity in overdose of dothiepin than of other tricyclic antidepressants. Lancet 1994, 343, 159-162.
8. Pinder, R. M. The toxicity of antidepressants in overdose: incidence and mechanisms-. Int. Rev. Psychiatry 1990, 2, 213227.
9. Kind, R.; Sorensen, J. The costs of depression. Int. Clin. Psychopharmacol. 1993, 7, 191-195.
10. Greenberg, P. E.; Stiglin, L. E.; Finkelstein, S. N.; Bemdt, E. R. The economic burden of depression in 1990. J. Clin. Psychiatry 1993, 54, 405-418.
11. McCombs, J. S.; Nichol, M. B.; Stimmel, G. L.; Sclar, D. A.; Beasley, C. M.; Gross, L. S. The cost of antidepressant drug therapy failure. A study of antidepressant use patterns in a Medicaid population. J. Clin. Psychiatry 1990, 51 (Suppl. 6), 60-69.
12. Greenberg, P. E.; Stiglin, L. E.; Finkelstein, S. N.; Berndt, E. R. Depression: A neglected major illness. J. Clin. Psychiatry 1993, 54, 419-424.
13. Leysen, D.; Pinder, R. M. Toward third generation antidepressants. Annu. Rep. Med. Chem. 1994, 29, 1-12.
14. Thompson, C.; Thompson, C. M. The prescription of antidepressants in general practice. I. A critical review. Hum. Psychopharmacol. 1989, 4, 91-102.
15. Nierenberg, A. A.; Amsterdam, J. D. Treatment-resistant depression: Definition and treatment approaches. J. Clin. Psychiatry 1990, 51 (Suppl. 6), 39-47.
16. Nemeroff, C. B. Augmentation regimes for depression. J. Clin. Psychiatry 1991, 52 (Suppl. 5), 21-27.
17. Nolen, W. A.; Haffmans, J. Treatment of resistant depression. Int. Clin. Psychopharmacol. 1989, 4, 217-228.
18. Austin, M. P. V.; Souza, F. G. M.; Goodwin, G. M. Lithium augmentation in antidepressant-resistant patients. A quantitative analysis. Br. J. Psychiatry 1991, 159, 510-514.
19. O’Brien, S.; McKeon, O.; O’Regan, M. The efficacy and tolerability of combined antidepressant treatment in different depressive subgroups. Br. J. Psychiatry 1993, 162, 362-368.
20. Tanghe, A.; Steeman, J.; Joosten, P.; van Renynghe de Voxvrie, G. Moclobemide and amitriptyline, alone or in combination, in therapy resistant depression. Presented at the CINP Regional Workshop on Critical Issues in the Treatment of Affective Disorders, Paris, France, March 1994; Abstracts, p 181.
21. Coles, R. J.; Young, J. R. P.; Sitsen, J. M. A.; Wright, P. Effectiveness of mianserin in combination with phenelzine in depressed outpatients. Biol. Psychiatry 1991, 29, 362S.
22. Lauritzen, L.; Clemmesen, L.; Klysner, R.; Loldrup, D.; Lunde, M.; Schaumberg, E.; Waarst, W.; Bech, P. Combined treatment with imipramine and mianserin. Pharmacopsychiatry 1992, 25, 182-186.
23. Lauritzen, L.; Bjerg Bendsen, B.; Vilmar, T.; Bjerg Bendsen, E.; Lunde, M.; Bech, P. Post-stroke depression: Combined treatment with imipramine or desipramine and mianserin, a controlled clinical study. Psychopharmacology 1994, 114, 119-122.
24. Feighner, J. P.; Boyer, W. F.; Tyler, D. L. Adverse consequences of fluoxetine-MAOI combination therapy. J. Clin. Psychiatry 1990, 5, 222-225.
25. Blier, P.; De Montigny, C. Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 1994, 15, 220226.
26. Moret, C.; Briley, M. The unique effect of methiothepin on the terminal serotonin autoreceptor in the rat hypothalamus could be an example of inverse agonism. J. Psychopharmacol. 1993, 7, 331-337.
27. De Boer, T.; Nefkens, F.; van Helvoirt, A. The ct2-adrenoceptor antagonist Org 3770 enhances serotonin transmission in vivo. Eur. J. Pharmacol. 1994, 253, R5-R6.
28. Haddjeri, N.; Blier, P.; Montigny, C. Effect of the a. 2-adrenoceptor antagonist Remeron on rat 5-HT neurotransmission (abstract). Soc. Neurosci. 1994, 20, 1553.
29. Artigas, F.; Perez, V.; Alvarez, E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch. Gen. Psychiatry 1994, 51, 248-251.
30. Hancock, A. A.; Buckner, S. A.; Giardina, W. J.; Brune, M. E.; Lee, J. Y.; Morse, P. A.; Oheim, K. W.; Stanisic, D. S.; Warner, R. B.; Kerkman, D. J.; DeBemardis, J. F. Preclinical pharmacological actions of (±)-(1′R, 3R)-3-phenyl-l-[(1′, 2′, 3′, 4′-tetrahydro-5′, 6′-methylene-dioxy-1′-naphthalenyl) methyl]pyrrolidine methanesulfonate (ABT-200), a potential antidepressant agent that antagonizes alpha-2 adrenergic receptors and inhibits the neuronal uptake of norepinephrine. J. Pharmacol. Exp. Ther. 1995, 272, 1160-1169.
31. Grebb, J. A.; Jasinsky, O.; Thys, R.; Kennedy, S.; Sramek, J. J.; Cutler, N. R.; Sebree, T.; Kashkin, K. B. A pilot efficacy study of A-75200 in patients with major depressive disorders. Presented at the CINP Regional Workshop on Critical Issues in the Treatment of Affective Disorders, Paris, France, March 1994; Abstracts, p 127.
32. Giardina, W. J.; Buckner, S. A.; Brune, M. E.; Hancock, A. A.; Wismer, C. T.; Milicic, I.; Rattin, J.; Roux, S.; Wettstein, J. G.; Meyer, M. D.; Porsolt, R. D.; Kerwin, J. F.; Williams, M. A-80426, a potent and selective a. 2-adrenoceptor antagonist with serotonin uptake blocking activity and putative antidepressant-like effects. II. Pharmacology profile. Drug Dev. Res. 1995, 35, 246-260.
33. Parmentier, M.; Libert, F.; Perret, J.; Eggerickx, D.; Ledent, C.; Schurmans, S.; Raspe, E.; Dumont, J. E.; Vassart, G. Cloning and characterisation of G protein-coupled receptors. In Advances in Second Messenger and Phosphoprotein Research, Brown, B. L., Dobson, P. R., Eds.; Raven Press: New York, 1993; Vol. 28, pp 11-18.
34. Karege, F.; Bovier, P.; Widmer, J.; Gaillard, J. M.; Tissot, R. Platelet membrane < X2-adrenergic receptors in depression. Psychiatry Res. 1992, 43, 243-252.
35. Coupland, N.; Glue, P.; Nutt, D. J. Challenge tests: assessment of the noradrenergic and GABA systems in depression and anxiety disorders. Mol. Aspects Med. 1992, 13, 221-247.
36. Ruffolo, R. R.; Nichols, A. J.; Stadel, J. M.; Hieble, J. P. Structure and function of a2-adrenoceptors. Pharmacol. Rev. 1991, 43, 475-505.
37. Levi, G.; Raiteri, M. Carrier-mediated release of neurotransmitters. Trends Neurol. Sci. 1993, 16, 415-419.
38. Raiteri, M.; Bonanno, G.; Maura, G.; Pende, M.; Andrioli, G. C.; Ruelle, A. Subclassification of release-regulating a. 2-adrenoceptors in human brain cortex. Br. J. Pharmacol. 1992, 107, 11461151.
39. Raiteri, M.; Maura, G.; Folghera, S.; Cavazzini, P.; Andrioli, G. C.; Schlicker, E.; Schalnus, R.; Gothert, M. Modulation of 5-hydroxytryptamine release by presynaptic inhibitory a. 2-adrenoceptors in the human cerebral cortex. Naunyn-Schmiede-berg’s Arch. Pharmacol. 1990, 342, 508-512.
40. Berlan, M.; Montastruc, J.-L.; Lafontan, M. Pharmacological prospects for a2-adrenoceptor antagonist therapy. Trends Pharmacol. Sci. 1992, 13, 277-282.
41. De Boer, T.; Maura, G.; Raiteri, M.; De Vos, C. J.; Wieringa, J.; Pinder, R. M. Neurochemical and autonomic pharmacological profiles of the 6-aza analogue of mianserin, Org 3770, and its enantiomers. Neuropharmacology 1988, 27, 399-408.
42. Montgomery, S. A. Theoretical and practical implications of a controlled trial of an (X2-adrenoceptor antagonist in the treatment of depression. In Clinical Pharmacology in Psychiatry, Dahl, S. G., Gram, L. F., Eds.; Springer-Verlag: Berlin, Germany, 1989; pp 105-108.
43. Grossman, F. A. Double-blind collaborative study with the NIMH and Friends Hospital comparing the clinical effects of idazoxan and bupropion in bipolar depressed patients. Presented at the CINP Regional Workshop on Critical Issues in the Treatment of Affective Disorders, Paris, France, March 1994; Abstracts, p 128.
44. Gothert, M.; Molderings, G. J. Involvement of presynaptic imidazoline receptors in the a. 2-adrenoceptor-independent inhibition of noradrenaline release by imidazoline derivatives. Naunyn-Schmiedeberg’s Arch. Pharmacol. 1991, 343, 271-282.
45. Li, G.; Regunathan, S.; Barrow, C. J.; Eshragi, J.; Cooper, R.; Reis, D. J. Agmatine: an endogenous clonidine-displacing substance in the brain. Science 1994, 263, 966-969.
46. Brown, C. M.; MacKinnon, A. C.; Redfern, W. S.; Hicks, P. E.; Kilpatrick, A. T.; Small, C.; Ramcharan, M.; Clague, R. U.; Clark, R. D.; McFarlane, C. B.; Spedding, M. The pharmacology of RS-15385-197, a potent and selective a2-adrenoceptor antagonist. Br. J. Pharmacol. 1993, 108, 516-525.
47. Nicholls, I. A.; Morrison, S. F.; Brinkworth, R. I.; Alewood, P. F.; Andrews, P. R. Central nervous system receptor binding profiles of some 2-amino-4-phenylquinolines: a novel class of 0: 2-adrenoceptor selective ligands. Life Sci. 1993, 53, PL 343-347.
48. Melloni, P.; Della Torre, A.; Meroni, M.; Pevarello, P.; Varasi, M.; Bonsignori, A.; Cini, M.; Vaghi, F.; Dostert, P. Synthesis of new fenmetazole analogues with potential mixed a. 2-adrenergic antagonistic activity and noradrenaline-uptake inhibiting properties. Eur. J. Med. Chem. 1991, 26, 207-213.
49. r and ct2-adrenergic receptors. FASEB J. 1992, 6, 832-839.
50. Harrison, J. K.; Pearson, W. R.; Lynch, K. R. Molecular characterization of ai- and a. 2-adrenoceptors. Trends Pharmacol. Sci. 1991, 12, 62-67.
51. Bylund, D. B.; Eikenberg, D. C.; Hieble, J. P.; Langer, S. Z.; Lefkowitz, R. J.; Minneman, K. P.; Molinoff, P. B.; Ruffolo, R. R.; Trendelenburg, U. International Union of Pharmacology Nomenclature of Adrenoceptors. Pharmacol. Rev. 1994, 46, 121-136.
52. Trendelenberg, A. U.; Trendelenberg, M.; Starke, K.; Limberger, N. Release-inhibiting a2-adrenoceptors at serotonergic axons in rat and rabbit brain cortex: evidence for pharmacological identity with a. 2-autoreceptors. Naunyn-Schmiedeberg’s Arch. Pharmacol. 1994, 349, 25-33.
53. 2D. Naunyn-Schmiedeberg’s Arch. Pharmacol. 1994, 349 (Suppl.), R79.
54. Heal, D. J.; Cheetham, S. C.; Butler, S. A.; Prow, M. W.; Buckett, W. R. Evidence to demonstrate that postsynaptic (adrenoceptors in the rat cortex are of the 0. 2D subtype. Br. J. Pharmacol. 1994, 112, 319P.
55. Simonneaux, V.; Ebadi, M.; Bylund, D. B. Identification and characterization of a2D-adrenergic receptors in bovine pineal gland. Mol. Pharmacol. 1991, 40, 235-241.
56. Maura, G.; Bonanno, G.; Raiteri, M. Presynaptic a2-adrenoceptors mediating inhibition of noradrenaline and 5-hydroxytryptamine release in rat cerebral cortex: further characterisation as different subtypes. Naunyn-Schmiedeberg’s Arch. Pharmacol. 1992, 345, 410-416.
57. 3H]serotonin release from rat brain synap-tosomes is not mediated by the ct2B-adrenoceptor subtype. Naunyn-Schmiedeberg’s Arch. Pharmacol. 1990, 342, 382-386.
58. De Montigny, C.; Mongeau, R.; Haddjeri, N.; Blier, P. Alteration of a2-heteroceptors on 5-HT terminals by antidepressant treatments: possible involvement in their therapeutic effect. Presented at the CINP Regional Workshop on Critical Issues in the Treatment of Affective Disorders, Paris, France, March 1994; Abstract, pp 72-73.
59. De Boer, T.; Nefkens, F.; Van Helvoirt, A. Differential effects of two a. 2-antagonist antidepressants, Remeron (Org 3770) and mianserin on noradrenergic and serotonergic transmission in vivo. Can. J. Physiol. Pharmacol. 1994, 72 (Suppl. 1), 439.
60. Blier, P.; Mongeau, R.; Weiss, M.; De Montigny, C. Modulation of serotonin transmission by presynaptic ci2-adrenergic receptors: A target for antidepressant pharmacotherapy? In New Pharmacological Approaches to the Therapy of Depressive Disorders; Mendlewicz, J., Brunello, N., Langer, S. Z., Racagni, G., Eds.; Karger: Basel, Switzerland, 1993; pp 74-82.
61. Fink, K.; Schultheiss, R.; Gothert, M. Stimulation of noradrenaline release in human cerebral receptors. Br. J. Pharmacol. 1992, 106, 67-72.
62. Fink, K.; Gothert, M. Modulation of N-methyl-D-aspartate (NMDA)-stimulated noradrenaline release in rat brain cortex by presynaptic ci2-adrenoceptors. Naunyn-Schmiedeberg’s Arch. Pharmacol. 1993, 348, 372-378.
63. Fink, K; Schlicke, E.; Gdthert, M. N-methyl-D-aspartate (NMDA)-stimulated noadrenaline (NA) release in rat brain is modulated by presynaptic H3-receptors. Naunyn-Schmiedeberg’s Arch. Pharmacol. 1994, 349, 113-117.
64. Itoh, Y.; Ogasawara, T.; Yamazaki, A.; Ukai, Y.; Miura, A.; Kimura, K. Enhancement of noradrenaline release from rat frontal cortex by thyrotropin releasing hormone and its analogue, (3R, 6R)-6-methyl-5-oxo-3-thiomorpholinocarbonyl-L-histidyl-L-prolinamide, as studied by intracerebral microdialysis. J. Pharmacol. Exp. Ther. 1994, 268, 255-261.
65. Trullas, R.; Faiman, C. P.; Viu, E. P.; Skolnik, P. Antidepressant properties of functional antagonists at the NMDA receptor complex. J. Neurochem. 1993, 61 (Suppl.), 550.
66. Nowak, G.; Layer, R. T.; Skolnik, P.; Paul, I. A. Adaptation of the NMDA receptor following chronic antidepressants. J. Neurochem. 1993, 61 (Suppl.), S51.
67. Gambarana, C.; Meloni, D.; De Montis, M. G.; Tagliamante, A. Mechanisms of neuronal plasticity implicated in the antidepressant effect of imipramine. J. Neurochem. 1993, 61 (Suppl.), S202.
68. B receptors. Trends Pharmacol. Sci. 1993, 14, 259-261.
69. B receptor antagonists: from synthesis to therapeutic applications. Trends Pharmacol. Sci. 1993, 14, 391-394.
70. Paykel, E. S.; Van Woerkom, A. E.; Walters, D. E.; White, W.; Mercer, J. Fengabine in depression: a placebo-controlled study of a GABA agonist. Hum. Psychopharmacol. 1991, 6, 147-154.
71. Squires, R. F.; Saederup, E. A review of the evidence for GABergic predominance/glutamatergic deficit as a common etiological factor in both schizophrenia and affective psychoses: more support for a continuum hypothesis of “functional” psychosis. Neurochem. Res. 1991, 16, 1099-1111.
72. Monteleone, P.; Maj, M.; Iovine, M.; Steardo, L. GABA, depression and the mechanism of action of antidepressant drugs: a neuroendocrine approach. J. Affective Disord. 1990, 20, 1-5.
73. Maura, G.; Pittaluga, A.; Ulivi, M.; Raiteri, M. Enhancement of endogenous GABA release from rat synaptosomal preparations is mediated by a. 2-adrenoceptors pharmacologically different from a. 2-autoreceptors. Eur. J. Pharmacol. 1988, 157, 23-29.
74. B type in human cerebral cortex. Br. J. Pharmacol. 1989, 96, 341-346.
75. Post, R. M.; Chuang, D. M. Mechanism of action of lithium: comparison and contrast with carbamazepine. In Lithium and The Celt Pharmacology and Biochemistry, Birch, N. J., Ed.; Academic Press: London, 1991; pp 199-241.
76. B receptor binding in rat frontal cortex. Br. J. Pharmacol. 1993, 110, 724-735.
77. Hartig, P. R. Molecular pharmacology of serotonin receptors. Experientia, Suppl. 1994, 71P, 93-102.
78. Rickels, K. Buspirone in clinical practice. J. Clin. Psychiatry 1990, Suppl. 51P, 51-54.
79. 1A receptors. J. Clin. Psychopharmacol. 1990, 10 (Suppl. 3), 6S-12S.
80. Rickels, K.; Amsterdam, J. D.; Clary, C.; Puzzuoli, G.; Schweizer, E. Buspirone in major depression: a controlled study. J. Clin. Psychiatry 1991, 52, 34-38.
81. Jenkins, S. W.; Robinson, D. S.; Fabre, L. F., Jr.; Andary, J. J.; Messina, M. E.; Reich, L. A. Gepirone in the treatment of major depression. J. Clin. Psychopharmacol. 1990, 10 (Suppl. 3), 77S-85S.
82. Heller, A. H.; Beneke, M.; Kuemmel, B.; Spencer, D.; Kurtz, N. M. Ipsapirone: evidence for efficacy in depression. Psychopharmacol. Bull. 1990, 26, 219-222.
83. Tollefson, G. D.; Lancaster, S. P.; Montague-Clouse, J. The association of buspirone and its metabolite 1-pyrimidinylpip-erazine in the remission of comorbid anxiety with depressive features and alcohol dependency. Psychopharmacol. Bull. 1991, 27, 163-170.
84. Jann, M. W. Buspirone, an update on a unique anxiolytic agent. Pharmacotherapy (Carlisle, Mass.) 1988, 8, 100-116.
85. 1A receptor agonist, in treatment-resistant depression. Int. Clin. Psychopharmacol. 1988, 8, 167-172.
86. 1A receptors. Eur. J. Pharmacol. 1994, 253, 139-147.
87. 1A receptor antagonists: Utility as research tools and therapeutic agents. Trends Pharmacol. Sci. 1993, 14, 441-448.
88. Munday, M. K.; Fletcher, A.; Marsden, C. A. Effect of the putative 5-HTu antagonists WAY 100135 and SDZ 216-525 on 5-HT neuronal firing in the guinea-pig dorsal raphe nucleus. Neuropharmacology 1994, 33, 61-66.
89. 1A antagonists. J. Pharmacol. Exp. Ther. 1994, 268, 337-352.
90. 1A receptors. Brain Res. 1990, 532, 191-196.
91. 1A receptors: Variations in intrinsic activity studied in transfected HeLa cells. Naunyn-Schmiedeberg’s Arch. Pharmacol. 1992, 345, 257-263.
92. 1A antagonist WAY100635 on 5-HT neuronal firing in the guinea-pig dorsal raphe nucleus. Br. J. Pharmacol. 1994, 112 (Suppl.), 93P.
93. 1A receptors. Med. Chem. Res. 1994, 4, 161-166.
94. Berendsen, H. H.; Broekkamp, C. L. Comparison of stimulus properties of fluoxetine and 5-HT receptor agonists in a conditioned taste aversion procedure. Eur. J. Pharmacol. 1994, 253, 83-89.
95. Jenck, F.; Broekkamp, C. L. E.; Van Delft, A. M. L. The effect of antidepressants on aversive periaqueductal gray stimulation in rats. Eur. J. Pharmacol. 1990, 177, 201-204.
96. Conn, P. J.; Sanders-Bush, E. Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT2 and 5-HTic) Receptors. J. Pharmacol. Exp. Ther. 1987, 242, 552-557.
97. Lee, H. S.; Bastani, B.; Friedman, L.; Ramirez, L.; Meltzer, H. Y. Effect of the serotonin agonist, MK-212, on body temperature in schizophrenia. Biol. Psychiatry 1992, 31, 460-470.
98. Bertolino, A.; Palermo, M.; Porro, V. Un nouvel antidepresseur non tricyclique, L’Oxaflozane, dans le traitement des syndromes anxio-dipressifs. (Oxaflozane, a new non tricyclic antidepressant in the treatment of anxiety-depressions syndromes.) Acta Ther. 1985, 11, 209-217.
99. Mellow, A. M.; Lawler, B. A.; Sunderland, T.; Mueller, E. A.; Molchan, S. E.; Murphy, D. L. Effects of daily oral m-chlorophe-nylpiperazine in elderly depressed patients; initial experience with a serotonin agonist. Biol. Psychiatry 1990, 28, 588-594.
100. Grignaschi, G.; Samanin, R. Role of 5-HT receptors in the effect of d-fenfluramine on feeding patterns in the rat. Eur. J. Pharmacol. 1992, 212, 287-289.
101. Kennett, G. A.; Wood, M. D.; Glen, A.; Grewal, S.; Forbes, I.; Gadre, A.; Blackburn, T. P. In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist. Br. J. Pharmacol. 1994, 111, 797-802.
102. Jenck, F.; Moreau, J.-L.; Mutel, V.; Martin, J. R. Brain 5-HTic receptors and antidepressants. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 1994, 18, 563-574.
103. Zohar, J.; Mueller, E. A.; Insel, T. R.; Zohar-Kadouch, R. C.; Murphy, D. L. Serotonergic responsitivity in obsessive-compulsive disorder: comparison of patients and healthy controls. Arch. Gen. Psychiatry 1987, 44, 946-951.
104. Murphy, D. L.; Mueller, E. A.; Hill, J. L.; Tolliver, T. J.; Jacobsen, F. M. Comparitive anxiogenic, neuroendocrine, and other physiological effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers. Psychopharmacology 1989, 43, 527-552.
105. Lawler, B. A.; Sunderland, T.; Mellow, A. M.; Molchan, S. E.; Martinez, R.; Murphy, D. L. A pilot placebo-controlled study of chronic m-CPP administration in Alzheimer’s disease. Biol. Psychiatry 1991, 30, 140-144.
106. Kahn, R. S.; Siever, L. J.; Gabriel, S.; Amin, F.; Stem, R. G.; DuMont, K.; Apter, S.; Davidson, M. Serotonin function in schizophrenia: Effects of meta-chlorophenylpiperazine in schizophrenic patients and healthy subjects. Psychiatry Res. 1992, 43, 1-12.
107. Costall, B.; Domeney, A. M.; Kelly, M. E.; Tomkins, D. M.; Naylor, R. J.; Wong, E. H.; Smith, W. L.; Whiting, R. L.; Eglen, R. M. The effect of the 5-HT3 receptor antagonist, RS-42358197, in animal models of anxiety. Eur. J. Pharmacol. 1993, 234, 91-99.
108. Maura, G.; Thelling, S.; Andrioli, G. C.; Ruelle, A.; Raiteri, M. Release-regulating serotonin 5-HTm autoreceptors in human cerebral cortex. J. Neurochem. 1993, 60, 1179-1182.
109. 1D antagonists. J. Med. Chem. 1994, 37, 2253-2257.
110. 1B receptors. Nature 1992, 360, 161-163.
111. Prien, R. F.; Gelenberg, A. J.; Alternatives to lithium in the preventive treatment of bipolar disorders. Am. J. Psychiatry 1989, 146, 840-848.
112. Bowden, C. L.; Brugger, A. M.; Swann, A. C.; Calabrese, J. R.; Janicak, P. E.; Petty, F.; Dilsaver, S. C.; Davis, J. M.; Rush, A. J.; Small, J. G.; Garza-Trevino, E. S.; Risch, S. C.; Goodrich, O. J.; Morris, D. D. Efficacy of divalproex vs lithium and placebo in the treatment of mania. J. Am. Med. Assoc. 1994, 271, 918924.
113. Hoschl, C. Do calcium antagonists have a place in the treatment of mood disorders? Drugs 1991, 42, 721-729.
114. Danoff, S. K.; Ross, C. A. The inositol triphosphate receptor gene family: implications for normal and abnormal brain function. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 1994, 18, 1-16.
115. Parthasarathy, L.; Vadnal, R. E.; Parthasarathy, R.; Devi, C. S. Biochemical and molecular properties of lithium-sensitive myoinositol monophosphatase. Life Sci. 1994, 16, 1127-1142.
116. Manji, H. K.; Lenox, R. H. Long-term action of lithium: a role for transcriptional and posttranscriptional factors regulated by protein kinase C. Synapse 1994, 16, 11-28.
117. Ozawa, H.; Katamura, Y.; Hatta, S.; Amemiya, N.; Saito, T.; Ohshika, H.; Takahata, N. Antidepressants directly influence in situ binding of guanine nucleotide in synaptic membrane. Life Sci. 1994, 54, 925-932.
118. Perez, J.; Mori, S.; Brunello, N.; Racagni, G. Cyclic AMP protein kinase as an intracellular target for the action of antidepressant drugs. In Critical Issues in the Treatment of Affective Disorders; Langer, S. Z., Brunello, N., Racagni, G., Mendlewicz, J., Eds.; Karger: Switzerland, 1994; Vol. 9, pp 110-117.
119. Beavo, J. A.; Reifsnyder, D. H. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol. Sci. 1990, 11, 150-155.
120. Levine, J.; Gonzalves, M.; Babur, I.; Stir, S.; Elizur, A.; Kofman, O.; Belmaker, R. H. Inositol 6g daily may be effective in depression but not in schizophrenia. Hum. Psychopharmacol. 1993, 8, 49-53.
121. Lesch, K.-P.; Aulakh, C. S.; Wolozin, B. L.; Murphy, D. L. Serotonin (5-HT) receptor, 5-HT transporter and G protein-effector expression: implications for depression. Pharmacol. Toxicol. 1992, 71 (Suppl. 1), 49-60.
122. Baldwin, J. M. The probable arrangement of the helices in G protein-coupled receptors. EMBO J. 1993, 12, 1693-1703.
123. Bimbaumer, L. Receptor-to-effector signaling through G proteins: roles for fly dimers as well as a subunits. Cell 1992, 71, 1069-1072.
124. Hepler, J. R.; Gilman, A. G. G proteins. Trends Biochem. Sci. 1992, 17, 383-387.
125. Simon, M. L.; Strathmann, M. P.; Gautam, N. Diversity of G proteins in signal transduction. Science 1991, 252, 802-808.
126. Laduron, P. M. Towards genomic pharmacology: from membranal to nuclear receptors. Adv. Drug. Res. 1992, 22, 107-148.
127. Lohse, M. J.; Benovic, J. L.; Codina, J.; Caron, M. G.; Lefkowitz, R. J. β-Arrestin: a protein that regulates β-adrenergic receptor function. Science 1990, 248, 1547-1550.
128. Inglese, J.; Freedman, N. J.; Koch, W. J.; Lefkowitz, R. J. Structure and mechanism of the G protein-coupled receptor kinases. J. Biol. Chem. 1993, 268, 23735-23738.
129. Girault, J.-A. Protein kinases and phosphatases. Neurotransmissions 1994, 10 (3), 1-5.
130. Zheng, J.; Knighton, D. R.; ten Eyck, L. F.; Karlsson, R.; Xuong, N.; Taylor, S. S.; Sowadski, J. M. Crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MgATP and peptide inhibitor. Biochemistry 1993, 32, 2154-2161.
131. Benovic, J. L.; Onorato, J.; Lohse, M. J.; Dohlman, H. G.; Staniszewiski, C.; Caron, M. G.; Lefkowitz, R. J. Synthetic peptides of the hamster-adrenoceptor as substrate and inhibitors of the β-adrenoceptor kinase. Br. J. Clin. Pharmacol. 1990, 30 (Suppl. 1), 3S-12S.
132. Travis, J. Novel anticancer agents move closer to reality. Science 1993, 260, 1877-1878.
133. Haga, T.; Haga, K.; Kameyama, K.; Nakata, H. Phosphorylation of muscarinic receptors: regulation by G proteins. Life Sci. 1993, 52, 421-428.
134. Simonds, W. F.; Manji, H. K.; Lupas, A. N.; Garritsen, A. G proteins and βARK: a new twist for the coiled coil. Trends Biochem. Sci. 1993, 18, 315-317.
135. Rossby, S. P.; Huang, M.; Burt, A.; Gillespie, D. D.; Sulser, D. The “serotonin/norepinephrine/glucocorticoid link” as a target for antidepressant drug action. Neuropsychopharmacology 1994, 10, 1738.
136. Young, L. T.; Li, P. P.; Kish, S. J.; Siu, K. P.; Warsh, J. J. Postmortem cerebral cortex Gs a-subunit levels are elevated in bipolar affective disorder. Brain Res. 1991, 553, 323-326.
137. Avissar, S.; Schreiber, G. Antidepressant and antibipolar treatments effects on receptor-coupled G proteins measured in lymphocytes of patients with mood disorders. Neuropsychopharmacology 1994, 10, 170S.
138. Pandey, G. N.; Pandey, S. C.; Janicak, P. G.; Davis, J. M. Signal transduction abnormalities in leukocytes of depressed patients. Neuropsychopharmacology 1994, 10, 15S.
139. Newman, M. E.; Belmaker, R. H. Effects of lithium in vitro and ex vivo on components of the adenylate cyclase system in membranes from the cerebral cortex of the rat. Neuropharmacology 1987, 26, 211-217.
140. Snyder, S. H. Second messengers and affective illness-Focus on the phosphoinositide cycle. Pharmacopsychiatry 1992, 25, 2528.
141. Racagni, G.; Brunello, N.; Tinelli, D.; Perez, J. New biochemical hypotheses on the mechanism of action of antidepressant drugs: cAMP-dependent phosphorylation system. Pharmacopsychiatry 1992, 25, 51-55.
142. Pollack, S. J.; Atack, J. R.; Knowles, M. R.; McAllister, G.; Ragan, C. I.; Baker, R.; Fletcher, S. R.; Iversen, L. L.; Broughton, H. B. Mechanism of inositolmonophosphatase, the putative target of lithium therapy. Proc. Natl. Acad. Sci. U. S. A. 1994, 91, 57665770.
143. Okada, F.; Tokumitsu, Y.; Ui, M. Possible involvement of pertussis toxin substrates (Gi, G.,) in desipramine-induced refractoriness of adenylate cyclase in cerebral cortices of rats. J. Neurochem. 1988, 51, 194-199.
144. Manji, H. K.; Chen, G.; Lesch, K. P.; Potter, W. Z. Signal transduction modulation by antidepressants: G proteins and protein kinase C isoenzymes as targets. Neuropsychopharmacology 1994, 10, 169S.
145. s and adenylyl cyclase. Neuropsychopharmacology 1994, 10, 580S.
146. oa subunits. Eur. J. Pharmacol. 1991, 207, 361-364.
147. a subunits that interact with G. J.; receptors, and effectors. Cell 1993, 73, 631-641.
148. Lambright, G. G.; Noel, J. P.; Hamm, H. E.; Sigler, P. B. Structural determinants for activation of the a-subunit of a heterotrimeric G protein. Nature 1994, 369, 621-628.
149. Noel, J. P.; Hamm, H. E.; Sigler, P. B. The 2. 2a crystal structure of transducin-a complexed with GTPyS. Nature 1993, 366, 654663.
150. Kurose, H.; Katada, T.; Amano, T,; Ui, M. Specific coupling by islet-activating protein, pertussis toxin of negative signal transduction via a-adrenergic, cholinergic, and opiate receptors in neuroblastoma x glioma hybrid cells. J. Biol. Chem. 1983, 258, 4870-4875.
151. Sullivan, K. A.; Miller, R. T.; Masters, S. B.; Beiderman, B.; Heideman, W.; Bourne, H. R. Identification of receptor contact site involved in receptor-G protein coupling. Nature 1987, 330, 758-760.
152. s. Functional studies with antibodies to the as carboxyl-terminal decapeptide. FEES Lett. 1989, 249, 189-194.
153. sa is involved in coupling to β-adrenoceptors. FEBS Lett. 1990, 261, 294-298.
154. a. Nature 1993, 363, 274-276.
155. Dratz, E. A.; Furstenau, J. E.; Lambert, C. G.; Thireault, D. L.; Rarick, H.; Schepers, T.; Pakhlevaniants, S.; Hamm, H. E. NMR structure of a receptor-bound G protein peptide. Nature 1993, 363, 276-281.
156. s-protein by site-specific synthetic peptides. FEBS Lett. 1989, 254, 89-94.
157. Malek, D.; Miinch, G.; Palm, D. Two sites in the third inner loop of the dopamine D2 receptor are involved in functional G protein-mediated coupling to adenylate cyclase. FEBS Lett. 1993, 325, 215-219.
158. Luttrel, L. M.; Ostrowski, J.; Cotecehia, S.; Kendall, H.; Lefkowtitz, R. J. Antagonism of catecholamine receptor signaling by expression of cytoplasmic domains of the receptor. Science 1993, 259, 1453-1457.
159. Okamoto, T.; Nishimoto, I. Native peptides that activate and antagonize G proteins. J. Neurochem. 1993, 61 (Suppl.), S118.
160. 0 by mastoparan, related amphiphilic peptides, and hydrophobic amines. J. Biol. Chem. 1990, 265, 14176-14186.
161. Mousli, M.; Bronner, C.; Bockaert, J.; Rouot, B.; Landry, Y. Interaction of substance P, compound 48/80 and mastoparan with the a-subunit C-terminus of G protein. Immunol. Lett. 1990, 25, 355-357.
162. Hageliiken, A.; Seifert, R. Amiodarone is a potent direct activator of pertussis toxin-sensitive G-proteins. Naunyn-Schmiedeberg’s Arch. Pharmacol. 1994, 349 (Suppl.), R18.
163. sa. Cell 1992, 68, 911-922.
164. Artemyyev, N. O.; Rarik, H. M.; Mills, J. S.; Skiba, N. P.; Hamm, H. E. Sites of interaction between rod G-protein a-subunit and cGMP-phosphodiesterase. Implications for the phosphodiesterase activation mechanism. J. Biol. Chem. 1992, 267, 25067-25072.
165. Artemyev, N. O.; Hamm, H. E. Probing G-protein function. Struct. Biol. 1994, 1, 752-754.
166. Murphy, B. E. P. Steroids and depression. J. Steroid Biochem. Mol. Biol. 1991, 38, 537-559.
167. Checkley, S. Neuroendocrine mechanisms and the precipitation of depression by life events. Br. J. Psychiatry 1992, 160 (Suppl. 15), 7-17.
168. Katho, R. G.; Jaeckle, R. S.; Lopez, J. F.; Meller, W. H. Consistent reduction of ACTH responses to stimulation with CHR, vasopressin and hypoglycaemia in patients with major depression. Br. J. Psychiatry 1989, 155, 468-478.
169. Roy, A.; Pickar, D.; Paul, S.; Doran, A.; Chrousos, G. P.; Gold, P. W. CSF corticotropin-releasing hormone in depressed patients and normal control subjects. Am. J. Psychiatry 1987, 144, 641645.
170. Nemeroff, C. B.; Owens, M. J.; Bissette, G.; Andorn, A. C.; Stanley, M. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch. Gen. Psychiatry 1988, 45, 577-579.
171. Ravaris, C. L.; Sateia, M. L.; Beroza, K. W.; Noordsy, D. L. Effect of ketoconazole on a hypophysectomized, hypercortisolemic, psychotically depressed woman. Arch. Gen. Psychiatry 1988, 45, 966-967.
172. Murphy, B. E. P.; Dhar, V.; Ghardirian, A. M.; Chouinard, D.; Keller, R. Response to steroid suppression in major depression resistant to antidepressant therapy. J. Clin. Psychopharmacol. 1991, 11, 121-126.
173. Molkowitz, O. M.; Reus, V. I.; Manfredi, F.; Ingbar, J.; Brizendine, L.; Weingartner, H. Ketoconazole administration in hypercortisolemic depression. Am. J. Psychiatry 1993, 150, 810812.
174. Thakore, J. H.; Dinan, T. G. Cortisol synthesis inhibition. A new treatment strategy for depression. J. Psychopharmacol. 1994, 8 (Suppl.), A50.
175. Murphy, B. E. P.; Filipini, D.; Ghadirian, A. M. Possible use of glucocorticoid receptor antagonists in the treatment of major depression: Preliminary results using RU486. J. Psychiatry Neurosci. 1993, 18, 209-213.
176. Teutsch, G.; Gaillard-Moguilewski, M.; Lemoine, G.; Nique, F.; Philibert, D. Design of ligands for the glucocorticoid and progestin receptors. Proc. Soc. Trans. 1991, 19, 901-905.
177. Sutanto, W.; De Kloet, E. R. Corticosteroid receptor antagonists: a current perspective. Pharmacy Wld. Sci. 1995, 17, 3141.
178. Barden, N. Antidepressant regulation of corticosteroid receptor gene expression: a mechanism for their normalization of HPA axis hyperactivity seen in depression. Neuropsychopharmacology 1994, 10, 6398.
179. Pearce, D. A mechanistic basis for distinct mineralocorticoid and glucocorticoid receptor transcriptional specificities. Steroids 1994, 59, 153-159.
180. Fisher, L. A. Corticotropin-releasing factor: endocrine and autonomic responses to stress. Trends Pharmacol. Sci. 1989, 10, 189-192.
181. Orth, D. N. Corticotropin-releasing hormone in humans. Endocrine Rev. 1992, 13, 164-191.
182. Nemeroff, C. B. New vistas in neuropeptide research in neuropsychiatry: Focus on corticotropin-releasing factor. Neuropsychopharmacology 1992, 6, 69-75.
183. Curtis, A. L.; Valentino, R. J. Acute and chronic effects of the atypical antidepressant, mianserin, on brain noradrenergic neurons. Psychopharmacology 1991, 103, 330-338.
184. Hernandez, J. F.; Kornreich, W.; Rivier, C.; Miranda, A.; Yamamoto, G.; Andrews, J.; Tache, Y.; Vale, W.; Rivier, J. Synthesis and relative potencies of new constrained CRF antagonists. J. Med. Chem. 1993, 36, 2860-2867.
185. Rivier, J.; Rivier, C.; Galyean, R.; Miranda, A.; Miller, C.; Craig, A. G.; Yamamoto, G.; Brown, M.; Vale, W. Single point D-substituted corticotropin-releasing factor analogues: Effects on potency and physiocochemical characteristics. J. Med. Chem. 1993, 36, 2851-2859.
186. Miranda, A.; Koerber, S. C.; Gulyas, J.; Lahrichi, S. L.; Craig, A. G.; Corrigan, A.; Hagler, A.; Rivier, C.; Vale, W.; Rivier, J. Conformationally restricted competitive antagonists of human/ rat corticotropin-releasing factor. J. Med. Chem. 1994, 37, 1450-1459.
187. Vita, N.; Laurent, P.; Lefort, S.; Chaim, P.; Lelias, J.-M.; Kaghad, M.; Le Fur, G.; Caput, D.; Ferrara, P. Primary structure and functional expression of mouse pituitary and human brain corticotropin-releasing factor receptors. FEBS Lett. 1993, 335, 1-7.
188. Prange, A. J.; Garbut, J. C.; Loosen, P. T. The hypothalamic-pituitary-thyroid axis in affective disorders. In Psychopharmacology. The third generation of progress; Meltzer, H. J., Ed.; Raven Press: New York, 1987; pp 629-636.
189. Gold, M. S.; Pottash, A.; Extein, I. Hypothyroidism and depression: Evidence from complete thyroid evaluation. J. Am. Med. Assoc. 1981, 245, 1919-1921.
190. Loosen, P. T.; Prange, A. J. Serum thyrotropin response to thyrotropin-releasing hormone in psychiatric patients: A review. Am. J. Psychiatry 1982, 139, 405-416.
191. Kirkegaard, C.; Faber, J.; Hummer, L.; Rogowski, P. Increased levels of TRH in cerebrospinal fluid from patients with endogenous depression. Psychoneuroendocrinology 1979, 4, 227-235.
192. Banki, C. M.; Bissette, G.; Arato, M.; Nemeroff, C. B. Elevation of immunoreactive CSF TRH in depressed patients. Am. J. Psychiatry 1988, 145, 1526-1531.
193. Roy, A.; Wolkowitz, O. M.; Bissette, G.; Nemeroff, C. B. Differences in CSF concentrations of thyrotropin-releasing hormone in depressed patients and normal subjects: Negative findings. Am. J. Psychiatry 1994, 151, 600-602.
194. Prange, A. J.; Loosen, P. T.; Wilson, J. C. The therapeutic use of hormones of the thyroid axis in depression. In Neurobiology of mood disorders; Post, R. M., Ballenger, J. C., Eds.; Williams & Wilkins: Baltimore, MD, 1984; pp 311-322.
195. Prange, A. J.; Wilson, J. C.; Lara, P. P. Effects of thyrotropinreleasing hormone in depression. Lancet 1972, 2, 999-1002.
196. Prange, A. J.; Wilson, I. C.; Rabon, A. M. Enhancement of imipramine antidepressant activity by thyroid hormone. Am. J. Psychiatry 1969, 126, 457-469.